公司資料
Neumora Therapeutics 股價、新聞與催化劑
- 股票代碼:
- NMRA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
1.63 USD (+7.59%)
收盤價
最後更新: 2026年8月21日
324M USD
市值
股價為何變動
As of Aug 21, 2026, NMRA closed up 7.59% at $1.63. No new same-company headline was identified in the current news window.
公司概覽
Novel-Mechanism Therapeutics
Neumora Therapeutics develops medicines targeting novel biological mechanisms across brain and centrally mediated diseases. Its current clinical and preclinical portfolio includes programs in neuropsychiatric disorders, neurodegeneration, obesity, and cardiometabolic disease.
NMRA-215
NMRA-215 is an NLRP3 inflammasome inhibitor being developed for obesity and cardiometabolic disease. The program is advancing toward first-in-human development after favorable preclinical findings.
NMRA-511
NMRA-511 is a vasopressin 1a receptor antagonist being developed for agitation associated with Alzheimer's disease. Neumora is evaluating higher doses in a multiple-ascending-dose expansion cohort involving healthy elderly participants before moving into a patient-based Phase 2 study.
NMRA-898
NMRA-898 is an M4 muscarinic receptor positive allosteric modulator being developed for schizophrenia. The ongoing Phase 1 multiple-ascending-dose study includes both healthy volunteers and patients with stable schizophrenia.
未來催化劑
- Phase 1 multiple-ascending-dose data for NMRA-898 in the second half of 2026.
- Submission of an IND for NMRA-215 in the fourth quarter of 2026.
- Multiple-ascending-dose expansion data for NMRA-511 in the fourth quarter of 2026.
- Initiation of the Phase 1 study of NMRA-215 by the end of 2026.
- Initiation of the Phase 2 study of NMRA-511 in Alzheimer's disease agitation by the end of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。